{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-005999","form_type":"8-K","ticker":"GKOS","cik":"0001192448","company_name":"GLAUKOS Corp","filed_at":"2025-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.721439+00:00","generated_at":"2026-05-23T02:01:44.062121+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Glaukos Q1 net sales record $106.7M (+25% YoY); net loss narrows to $0.32/sh from $0.82","bullets":["Record Q1 net sales $106.7M, up 25% reported and 26% constant currency vs $85.6M last year.","U.S. Glaucoma sales $59.1M (+41% YoY); total Glaucoma $88.1M (+31% YoY).","GAAP net loss $18.1M ($0.32/sh) vs $40.8M ($0.82/sh) in Q1 2024; non-GAAP net loss $12.6M ($0.22).","Gross margin ~77%; non-GAAP gross margin ~82%; operating loss improved to $20.7M from $39.1M.","Reaffirmed FY 2025 net sales guidance of $475M-$485M; cash $303.4M with no debt."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-005999","json":"https://secwatch.observer/filing/0001558370-25-005999.json","markdown":"https://secwatch.observer/filing/0001558370-25-005999.md","text":"https://secwatch.observer/filing/0001558370-25-005999.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1192448/000155837025005999/0001558370-25-005999-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1192448/000155837025005999/gkos-20250430x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T02:01:44.062121+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}